1. Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution
- Author
-
Silong Lou, Siqing Huang, Jiagang Liu, Xing Cheng, and M.D. Haifeng chen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,medicine ,Temozolomide ,Humans ,Spinal Cord Neoplasms ,Single institution ,Karnofsky Performance Status ,Antineoplastic Agents, Alkylating ,Retrospective Studies ,Chemotherapy ,business.industry ,Laminectomy ,Retrospective cohort study ,Partial resection ,Middle Aged ,medicine.disease ,Spinal cord ,Combined Modality Therapy ,Surgery ,Radiation therapy ,Dacarbazine ,medicine.anatomical_structure ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Neurology (clinical) ,business ,Glioblastoma ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background and Objective Primary spinal cord (PSC) glioblastoma multiforme (GBM) is extremely rare and accounts for only 1.5% of all spinal cord tumors. Therefore, its treatment is still ill defined. To elucidate prognostic factors, we performed a single-institutional retrospective review of the largest series to date of patients with PSC GBM who underwent surgical resection in West China Hospital between 2008 and 2014. A total of 14 patients with PSC GBM were reviewed. Methods Demographic, operative, and postoperative factors were recorded. Overall survival (OS) and progression-free survival (PFS) were calculated and compared with the Kaplan-Meier method. Results Eight males (57%) and 6 females (43%) were involved in the study. Their median age was 28 years (range, 14–56 years). Median Karnofsky Performance Status score was 60 (range, 20–90). Four patients (28.6%) received gross total resection, 5 (35.7%) partial resection, and the remaining 5 (35.7%) biopsy only. Nine patients (64.3%) received postoperative radiotherapy and chemotherapy, 3 (21.4%) chemotherapy only, and 2 (14.3%) neither. Median follow-up period was 15 months (range, 5–26 months). One-year and 2-year survival was 78.5% (11/14) and 7.1% (1/14), respectively. Median OS was 15 months, and median PFS 8 months. Univariate log-rank analysis showed that OS and PFS were significantly associated with patients' age (P = 0.007 and P = 0.04, respectively) and postoperative radiotherapy (P = 0.001 and P = 0.002, respectively). However, preoperative Karnofsky Performance Status score affected only OS and did not affect PFS (P = 0.033 and P = 0.106, respectively). Conclusions According to our study, the combination of postoperative radiotherapy and temozolomide chemotherapy can improve prognosis and may serve as a feasible postoperative adjuvant treatment of PSC GBM.
- Published
- 2016